Interlinking of diabetes mellitus and cancer: An overview.
cancer
diabetes
insulin
insulin like growth factor 1
sugar
Journal
Cell biochemistry and function
ISSN: 1099-0844
Titre abrégé: Cell Biochem Funct
Pays: England
ID NLM: 8305874
Informations de publication
Date de publication:
Jul 2023
Jul 2023
Historique:
revised:
29
04
2023
received:
05
04
2023
accepted:
02
05
2023
medline:
13
7
2023
pubmed:
18
5
2023
entrez:
18
5
2023
Statut:
ppublish
Résumé
Cancer and diabetes mellitus (DM) are among the leading causes of mortality and morbidity in the global arena. Lately, several studies demonstrated that DM could promote cancer. However, the exact mechanism(s) highlighting this association are largely untouched and require comprehensive detailing. In the present review, we aimed to explore and decipher the possible mechanism of DM an cancer association. Hyperglycemia could be a subordinate plausible explanation of carcinogenesis in the diabatic patient. It is well known that high glucose levels may help in cancer proliferation. In addition, chronic inflammation, the other well-known factor of diabetes, could also play a role in carcinogenesis. Moreover, the numerous medicines to treat diabetes either increase or reduce cancer risk. Insulin is one of the potent growth factors that promotes cell propagation and induces cancer directly or via insulin like growth factor-1. On the other hand, hyperinsulinemia leads to an increased activity of growth factor-1 by inhibiting growth factor binding protein-1. To improve cancer prognosis, individuals with diabetes should be screened to discover cancer at an early stage and treated appropriately.
Substances chimiques
Insulin
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
506-516Informations de copyright
© 2023 John Wiley & Sons Ltd.
Références
IDF Diabetes Atlas | Tenth Edition. (n.d.). Retrieved January 29 2023, from https://diabetesatlas.org/
Gurney J, Stanley J, Teng A, et al. Cancer and diabetes co-occurrence: a national study with 44 million person-years of follow-up. PLoS One. 2022;17(11):e0276913. doi:10.1371/JOURNAL.PONE.0276913
Hernández-Garduño E. The association between diabetes and cancer in Mexico: analysis using death certificate databases, 2009-2017. J Cancer Res Ther. 2021;17(6):1397-1403. doi:10.4103/JCRT.JCRT_878_19
Romanová A, Malinovská J, Lustigová M, et al. Colorectal cancer in patients with diabetes-epidemiology, pathophysiology and applications for clinical practice. Vnitřní lékařství. 2022;68(2):116-122. doi:10.36290/vnl.2022.022
Zhu B, Qu S. The relationship between diabetes mellitus and cancers and its underlying mechanisms. Front Endocrinol. 2022;13:75. doi:10.3389/FENDO.2022.800995/BIBTEX
Giovannucci E, Harlan DM, Archer MC, et al. Diabetes and cancer: a consensus report. CA Cancer J Clin. 2010b;60(4):207-221. doi:10.3322/CAAC.20078
Sciacca L, Vigneri R, Tumminia A, et al. Clinical and molecular mechanisms favoring cancer initiation and progression in diabetic patients. Nutr Metab Cardiovasc Dis. 2013;23(9):808-815. doi:10.1016/J.NUMECD.2013.05.006
Gutiérrez-Salmerón M, Chocarro-Calvo A, García-Martínez JM, de la Vieja A, García-Jiménez C. Bases epidemiológicas y mecanismos moleculares implicados en las asociaciones de obesidad y diabetes con cáncer. Endocrinología, Diabetes y Nutrición. 2017;64(2):109-117. doi:10.1016/J.ENDINU.2016.10.005
Maghlaperidze Z, Kapetivadze V, Tabukashvili R, Lazashvili T, Kuparadze M, Gratiashvili E. The role of insulin-like growth factor-1 and insulin in development of colorectal cancer. Georgian Med News. 2021;315:26-29. https://pubmed.ncbi.nlm.nih.gov/34365420/
Argirion I, Weinstein SJ, Männistö S, Albanes D, Mondul AM. Serum insulin, glucose, indices of insulin resistance, and risk of lung cancer. Cancer Epidemiol Biomarkers Prev. 2017;26(10):1519-1524. doi:10.1158/1055-9965.EPI-17-0293
He XX, Tu SM, Lee MH, Yeung SCJ. Thiazolidinediones and metformin associated with improved survival of diabetic prostate cancer patients. Ann Oncol. 2011;22(12):2640-2645. doi:10.1093/ANNONC/MDR020
Hsu SK, Cheng KC, Mgbeahuruike MO, et al. New insight into the effects of metformin on diabetic retinopathy, aging and cancer: nonapoptotic cell death, immunosuppression, and effects beyond the AMPK pathway. Int J Mol Sci. 2021;22(17):9453. doi:10.3390/IJMS22179453
Landman GWD, Kleefstra N, Van Hateren KJJ, Groenier KH, Gans ROB, Bilo HJG. Metformin associated with lower cancer mortality in type 2 diabetes. Diabetes Care. 2010;33(2):322-326. doi:10.2337/DC09-1380
Libby G, Donnelly LA, Donnan PT, Alessi DR, Morris AD, Evans JMM. New users of metformin are at low risk of incident cancer. Diabetes Care. 2009;32(9):1620-1625. doi:10.2337/DC08-2175
Lu F, Chen W, Jiang T, et al. Expression profile, clinical significance and biological functions of IGF2BP2 in esophageal squamous cell carcinoma. Exp Ther Med. 2022;23(4):252. doi:10.3892/ETM.2022.11177
Onitilo AA, Engel JM, Glurich I, Stankowski RV, Williams GM, Doi SA. Diabetes and cancer I: risk, survival, and implications for screening. Cancer Causes & Control: CCC. 2012a;23(6):967. doi:10.1007/S10552-012-9972-3
Qin L, Wang Y, Tao L, Wang Z. AKT down-regulates insulin-like growth factor-1 receptor as a negative feedback. J Biochem. 2011;150(2):151-156. doi:10.1093/JB/MVR066
Supabphol S, Seubwai W, Wongkham S, Saengboonmee C. High glucose: an emerging association between diabetes mellitus and cancer progression. J Mol Med. 2021;99(9):1175-1193. doi:10.1007/S00109-021-02096-W
Chettouh H, Fartoux L, Aoudjehane L, et al. Mitogenic insulin receptor-A is overexpressed in human hepatocellular carcinoma due to EGFR-mediated dysregulation of RNA splicing factors. Cancer Res. 2013;73(13):3974-3986. doi:10.1158/0008-5472.CAN-12-3824
Cai W, Sakaguchi M, Kleinridders A, et al. Domain-dependent effects of insulin and IGF-1 receptors on signalling and gene expression. Nat Commun. 2017;8:14892. doi:10.1038/NCOMMS14892
de Meyts P. The Insulin Receptor and Its Signal Transduction Network. [Updated 2016 Apr 27]. In: Feingold KR, Anawalt B, Blackman MR, eds. Endotext [Internet]. MDText.com, Inc.; 2000. https://www.ncbi.nlm.nih.gov/books/NBK378978/
Djiogue S, Nwabo Kamdje AH, Vecchio L, et al. Insulin resistance and cancer: the role of insulin and IGFs. Endocr Relat Cancer. 2013;20(1):R1-R17. doi:10.1530/ERC-12-0324
Novosyadlyy R, LeRoith D. Hyperinsulinemia and type 2 diabetes: impact on cancer. Cell Cycle. 2010;9(8):1449-1450. doi:10.4161/CC.9.8.11512
Choi JH, Park JY. Insulin-like growth factor-1 receptor targeted fluorescent imaging for gallbladder cancer in orthotopic mouse models. Gut Liver. 2022;16(4):606-612. doi:10.5009/GNL210164
Ipsa E, Cruzat VF, Kagize JN, Yovich JL, Keane KN. Growth hormone and insulin-like growth factor action in reproductive tissues. Front Endocrinol. 2019;10:777. doi:10.3389/FENDO.2019.00777/BIBTEX
Chaves FM, Wasinski F, Tavares MR, et al. Effects of the isolated and combined ablation of growth hormone and IGF-1 receptors in somatostatin neurons. Endocrinology. 2022;163(5). doi:10.1210/ENDOCR/BQAC045
Gallagher EJ, LeRoith D. Hyperinsulinaemia in cancer. Nat Rev Cancer. 2020;20(11):629-644. doi:10.1038/s41568-020-0295-5
Chen R, Brentnall TA, Pan S, et al. Quantitative proteomics analysis reveals that proteins differentially expressed in chronic pancreatitis are also frequently involved in pancreatic cancer. Mol Cell Proteomics. 2007;6(8):1331-1342. doi:10.1074/mcp.M700072-MCP200
Ogunleye AA, Ogston SA, Morris AD, Evans JMM. A cohort study of the risk of cancer associated with type 2 diabetes. Br J Cancer. 2009;101(7):1199-1201. doi:10.1038/sj.bjc.6605240
Gupta S, Vittinghoff E, Bertenthal D, Corley D, Shen H, Walter LC, McQuaid K. New-onset diabetes and pancreatic cancer. Clin Gastroenterol Hepatol. 2006;4(11):1366-1372. doi:10.1016/J.CGH.2006.06.024
Ben Q, Xu M, Ning X, et al. Diabetes mellitus and risk of pancreatic cancer: a meta-analysis of cohort studies. European Journal of Cancer (Oxford, England: 1990). 2011;47(13):1928-1937. doi:10.1016/J.EJCA.2011.03.003
Batabyal P, Vander Hoorn S, Christophi C, Nikfarjam M. Association of diabetes mellitus and pancreatic adenocarcinoma: a meta-analysis of 88 studies. Ann Surg Oncol. 2014;21(7):2453-2462. doi:10.1245/S10434-014-3625-6
Pannala R, Leirness JB, Bamlet WR, Basu A, Petersen GM, Chari ST. Prevalence and clinical profile of pancreatic cancer-associated diabetes mellitus. Gastroenterology. 2008;134(4):981-987. doi:10.1053/J.GASTRO.2008.01.039
Davila JA, Morgan RO, Shaib Y, McGlynn KA, El-Serag HB. Diabetes increases the risk of hepatocellular carcinoma in the United States: a population based case control study. Gut. 2005;54(4):533-539. doi:10.1136/GUT.2004.052167
Han H, Deng H, Han T, Zhao H, Hou F, Qi X. Association between hepatocellular carcinoma and type 2 diabetes mellitus in Chinese hepatitis B virus cirrhosis patients: a case-control study. Med Sci Monit: Int Med J Exp Clin Res. 2017;23:3324. doi:10.12659/MSM.902440
Zhu B, Wu X, Wu B, Pei D, Zhang L, Wei L. The relationship between diabetes and colorectal cancer prognosis: a meta-analysis based on the cohort studies. PLOS ONE. 2017;12(4):e0176068. doi:10.1371/JOURNAL.PONE.0176068
Guraya SY. Association of type2 diabetes mellitus and the risk of colorectal cancer: a meta-analysis and systematic review. World J Gastroenterol. 2015;21(19):6026. doi:10.3748/WJG.V21.I19.6026
Hardefeldt PJ, Edirimanne S, Eslick GD. Diabetes increases the risk of breast cancer: a meta-analysis. Endocr-Relat Cancer. 2012;19(6):793-803. doi:10.1530/ERC-12-0242
Larsson SC, Mantzoros CS, Wolk A. Diabetes mellitus and risk of breast cancer: a meta-analysis. Int J Cancer. 2007;121(4):856-862. doi:10.1002/IJC.22717
Lee J, Giovannucci E, Jeon JY. Diabetes and mortality in patients with prostate cancer: a meta-analysis. Springer Plus. 2016;5(1):1-11. doi:10.1186/S40064-016-3233-Y/FIGURES/3
Bonovas S, Filioussi K, Tsantes A. Diabetes mellitus and risk of prostate cancer: a meta-analysis. Diabetologia. 2004;47(6):1071-1078. doi:10.1007/S00125-004-1415-6
Zhang H, Fagan DH, Zeng X, Freeman KT, Sachdev D, Yee D. Inhibition of cancer cell proliferation and metastasis by insulin receptor downregulation. Oncogene. 2010;29(17):2517-2527. doi:10.1038/ONC.2010.17
Ramteke P, Deb A, Shepal V, Bhat MK. Hyperglycemia associated metabolic and molecular alterations in cancer risk, progression, treatment, and mortality. Cancers. 2019a;11(9):1402. doi:10.3390/CANCERS11091402
Suh S, Kim KW. Diabetes and cancer: cancer should be screened in routine diabetes assessment. Diabetes Metab J. 2019b;43(6):733-743. doi:10.4093/DMJ.2019.0177
Tzivion G, Dobson M, Ramakrishnan G. FoxO transcription factors; regulation by AKT and 14-3-3 proteins. Biochim Biophys Acta. 2011;1813(11):1938-1945. doi:10.1016/J.BBAMCR.2011.06.002
Koo DH, Han K, Park CY. Impact of cumulative hyperglycemic burden on the pancreatic cancer risk: a nationwide cohort study. Diabetes Res Clin Pract. 2023;195:110208. doi:10.1016/J.DIABRES.2022.110208
Fleming HE, Janzen V, Lo Celso C, et al. Wnt signaling in the niche enforces hematopoietic stem cell quiescence and is necessary to preserve self-renewal in vivo. Cell Stem Cell. 2008;2(3):274-283. doi:10.1016/J.STEM.2008.01.003
Saydah SH, Platz EA, Rifai N, Pollak MN, Brancati FL, Helzlsouer KJ. Association of markers of insulin and glucose control with subsequent colorectal cancer risk. Cancer Epidemiol Biomarkers Prev. 2003;12(5):412-418. https://pubmed.ncbi.nlm.nih.gov/12750235/
Yamasaki K, Hayashi Y, Okamoto S, Osanai M, Lee GH. Insulin-independent promotion of chemically induced hepatocellular tumor development in genetically diabetic mice. Cancer Sci. 2010;101(1):65-72. doi:10.1111/J.1349-7006.2009.01345.X
Vigneri P, Frasca F, Sciacca L, Pandini G, Vigneri R. Diabetes and cancer. Endocr Relat Cancer. 2009;16(4):1103-1123. doi:10.1677/ERC-09-0087
Johnson JA, Bowker SL. Intensive glycaemic control and cancer risk in type 2 diabetes: a meta-analysis of major trials. Diabetologia. 2011;54(1):25-31. doi:10.1007/S00125-010-1933-3
Ramteke P, Deb A, Shepal V, Bhat MK. Hyperglycemia associated metabolic and molecular alterations in cancer risk, progression, treatment, and mortality. Cancers. 2019b;11(9):1402. doi:10.3390/CANCERS11091402
Ward PS, Thompson CB. Metabolic reprogramming: a cancer hallmark even warburg did not anticipate. Cancer Cell. 2012;21(3):297-308. doi:10.1016/J.CCR.2012.02.014
Anagnostou SH, Shepherd PR. Glucose induces an autocrine activation of the Wnt/β-catenin pathway in macrophage cell lines. Biochem J. 2008;416(2):211-218. doi:10.1042/BJ20081426
Chocarro-Calvo A, García-Martínez JM, Ardila-González S, De la Vieja A, García-Jiménez C. Glucose-induced β-catenin acetylation enhances Wnt signaling in cancer. Mol Cell. 2013;49(3):474-486. doi:10.1016/J.MOLCEL.2012.11.022
Piconese S, Cammarata I, Barnaba V. Viral hepatitis, inflammation, and cancer: a lesson for autoimmunity. J Autoimmun. 2018;95:58-68. doi:10.1016/J.JAUT.2018.10.021
Cao C, Tian B, Geng X, et al. IL-17-Mediated inflammation promotes cigarette smoke-induced genomic instability. Cells. 2021;10(5):1173. doi:10.3390/CELLS10051173
Del Prete A, Allavena P, Santoro G, Fumarulo R, Corsi MM, Mantovani A. Molecular pathways in cancer-related inflammation. Biochem Med. 2011;21(3):264-275. doi:10.11613/BM.2011.036
Moore MM, Chua W, Charles KA, Clarke SJ. Inflammation and cancer: causes and consequences. Clin Pharm Ther. 2010;87(4):504-508. doi:10.1038/CLPT.2009.254
Anthony E, Reece JC, Milanzi E, et al. Body mass index, sex, non-steroidal anti-inflammatory drug medications, smoking and alcohol are differentially associated with World Health Organisation criteria and colorectal cancer risk in people with serrated polyposis syndrome: an Australian case-control study. BMC Gastroenterol. 2022;22(1):489. doi:10.1186/S12876-022-02557-7
Murphy MA, Trabert B, Yang HP, et al. Non-steroidal anti-inflammatory drug use and ovarian cancer risk: findings from the NIH-AARP Diet and Health Study and systematic review. Cancer Causes Control. 2012;23(11):1839-1852. doi:10.1007/S10552-012-0063-2
Setiawan VW, Matsuno RK, Lurie G, et al. Use of nonsteroidal anti-inflammatory drugs and risk of ovarian and endometrial cancer: the multiethnic cohort. Cancer Epidemiol Biomarkers Prev. 2012;21(9):1441-1449. doi:10.1158/1055-9965.EPI-12-0390-T
Afify SM, Hassan G, Seno A, Seno M. Cancer-inducing niche: the force of chronic inflammation. Br J Cancer. 2022;127(2):193-201. doi:10.1038/s41416-022-01775-w
Chobot A, Górowska-Kowolik K, Sokołowska M, Jarosz-Chobot P. Obesity and diabetes-not only a simple link between two epidemics. Diabetes Metab Res Rev. 2018;34(7):e3042. doi:10.1002/DMRR.3042
Singh N, Baby D, Rajguru J, Patil P, Thakkannavar S, Pujari V. Inflammation and cancer. Ann Afr Med. 2019;18(3):121-126. doi:10.4103/AAM.AAM_56_18
Nunez NP, Oh WJ, Rozenberg J, et al. Accelerated tumor formation in a fatless mouse with type 2 diabetes and inflammation. Cancer Res. 2006;66(10):5469-5476. doi:10.1158/0008-5472.CAN-05-4102
Kang C, LeRoith D, Gallagher EJ. Diabetes, obesity, and breast cancer. Endocrinology. 2018;159(11):3801-3812. doi:10.1210/EN.2018-00574
Ferguson RD, Novosyadlyy R, Fierz Y, et al. Hyperinsulinemia enhances c-Myc-mediated mammary tumor development and advances metastatic progression to the lung in a mouse model of type 2 diabetes. Breast Cancer Res. 2012;14(1):R8. doi:10.1186/BCR3089
Cleary MP, Grossmann ME. Obesity and breast cancer: the estrogen connection. Endocrinology. 2009;150(6):2537-2542. doi:10.1210/EN.2009-0070
Noto H, Tsujimoto T, Sasazuki T, Noda M. Significantly increased risk of cancer in patients with diabetes mellitus: a systematic review and meta-analysis. Endocrine Practice. 2011;17(4):616-628. doi:10.4158/EP10357.RA
Abudawood M. Diabetes and cancer: a comprehensive review. J Res Med Sci. 2019;24(1):94. doi:10.4103/JRMS.JRMS_242_19
Mantovani A, Targher G. Type 2 diabetes mellitus and risk of hepatocellular carcinoma: spotlight on nonalcoholic fatty liver disease. Ann Transl Med. 2017;5(13):270. doi:10.21037/ATM.2017.04.41
Kramer JR, Natarajan Y, Dai J, et al. Effect of diabetes medications and glycemic control on risk of hepatocellular cancer in patients with nonalcoholic fatty liver disease. Hepatology. 2022;75(6):1420-1428. doi:10.1002/HEP.32244
McGlynn KA, Petrick JL, El-Serag HB. Epidemiology of hepatocellular carcinoma. Hepatology. 2021;73(Suppl 1 suppl 1):4-13. doi:10.1002/HEP.31288
Adamek A, Kasprzak A. Insulin-like growth factor (IGF) system in liver diseases. Int J Mol Sci. 2018;19(5):1308. doi:10.3390/IJMS19051308
Burris J, Shikany JM, Rietkerk W, Woolf K. A low glycemic index and glycemic load diet decreases insulin-like growth Factor-1 among adults with moderate and Severe Acne: a short-duration, 2-week randomized controlled trial. J Acad Nutr Diet. 2018;118(10):1874-1885. doi:10.1016/J.JAND.2018.02.009
Weng CJ, Hsieh YH, Tsai CM, et al. Relationship of insulin-like growth factors system gene polymorphisms with the susceptibility and pathological development of hepatocellular carcinoma. Ann Surg Oncol. 2010;17(7):1808-1815. doi:10.1245/S10434-009-0904-8
Papa S, Bubici C, Zazzeroni F, Franzoso G. Mechanisms of liver disease: cross-talk between the NF-κB and JNK pathways. bchm. 2009;390(10):965-976. doi:10.1515/BC.2009.111
Sun HJ, Ohrr H, Sull JW, Yun JE, Ji M, Samet JM. Fasting serum glucose level and cancer risk in Korean men and women. JAMA. 2005;293(2):194-202. doi:10.1001/JAMA.293.2.194
Shams MEE. Type 2 diabetes mellitus-induced hyperglycemia in patients with NAFLD and normal LFTs: relationship to lipid profile, oxidative stress and pro-inflammatory cytokines. Sci Pharm. 2011;79(3):623-634. doi:10.3797/SCIPHARM.1104-21
Jiang Y, Ben Q, Shen H, Lu W, Zhang Y, Zhu J. Diabetes mellitus and incidence and mortality of colorectal cancer: a systematic review and meta-analysis of cohort studies. Eur J Epidemiol. 2011;26(11):863-876. doi:10.1007/S10654-011-9617-Y
Sangnes DA, Lundervold K, Bekkelund M, et al. Gastrointestinal transit and contractility in diabetic constipation: a wireless motility capsule study on diabetes patients and healthy controls. United European Gastroenterol J. 2021;9(10):1168-1177. doi:10.1002/UEG2.12169
Yamada E, Namiki Y, Takano Y, et al. Clinical factors associated with the symptoms of constipation in patients with diabetes mellitus: A multicenter study. J Gastroenterol Hepatol. 2018;33(4):863-868. doi:10.1111/JGH.14022
Ocvirk S, O'Keefe SJ. Influence of bile acids on colorectal cancer risk: potential mechanisms mediated by diet-gut microbiota interactions. Current Nutrition Reports. 2017;6(4):315-322. doi:10.1007/S13668-017-0219-5
Wang C, Wang X, Gong G, et al. Increased risk of hepatocellular carcinoma in patients with diabetes mellitus: a systematic review and meta-analysis of cohort studies. Int J Cancer. 2012;130(7):1639-1648. doi:10.1002/IJC.26165
De Bruijn KMJ, Arends LR, Hansen BE, Leeflang S, Ruiter R, Van Eijck CHJ. Systematic review and meta-analysis of the association between diabetes mellitus and incidence and mortality in breast and colorectal cancer. Br J Surg. 2013;100(11):1421-1429. doi:10.1002/BJS.9229
Zhang F, Yang Y, Skrip L, et al. Diabetes mellitus and risk of prostate cancer: an updated meta-analysis based on 12 case-control and 25 cohort studies. Acta Diabetologica. 2012;49(1):235-246. doi:10.1007/S00592-012-0439-5/METRICS
Shum HCE, Wu K, Vadgama J, Wu Y. Potential therapies targeting the metabolic reprogramming of diabetes-associated breast cancer. J Pers Med. 2023;13(1):157. doi:10.3390/JPM13010157
Lao C, Gurney J, Stanley J, et al. Association of diabetes and breast cancer characteristics at diagnosis. Cancer Causes Control. 2023;34(2):103-111. doi:10.1007/S10552-022-01654-Y/METRICS
Xiao Y, Wang H, Tang Y, et al. Increased risk of diabetes in cancer survivors: a pooled analysis of 13 population-based cohort studies. ESMO Open. 2021;6(4):100218. doi:10.1016/J.ESMOOP.2021.100218
Rebecca EJ, Lukanova A, Dossus L, et al. Postmenopausal serum sex steroids and risk of hormone receptor-positive and -negative breast cancer: a nested case-control study. Cancer Prev Res (Phila). 2011;4(10):1626-1635. doi:10.1158/1940-6207.CAPR-11-0090
Allen NE, Key TJ, Dossus L, et al. Endogenous sex hormones and endometrial cancer risk in women in the European prospective investigation into cancer and nutrition (EPIC). Endocr Relat Cancer. 2008;15(2):485-497. doi:10.1677/ERC-07-0064
Bao C, Yang X, Xu W, et al. Diabetes mellitus and incidence and mortality of kidney cancer: a meta-analysis. J Diabetes Complications. 2013;27(4):357-364. doi:10.1016/J.JDIACOMP.2013.01.004
Chow WH, Gridley G, Fraumeni JF, Järvholm B. Obesity, hypertension, and the risk of kidney cancer in men. N Engl J Med. 2000;343(18):1305-1311. doi:10.1056/NEJM200011023431804
Russo P. End stage and chronic kidney disease: associations with renal cancer. Front Oncol. 2012;2:28. doi:10.3389/FONC.2012.00028
Zhu Z, Zhang X, Shen Z, et al. Diabetes mellitus and risk of bladder cancer: a meta-analysis of cohort studies. PLoS One. 2013;8(2):e56662. doi:10.1371/JOURNAL.PONE.0056662
El-Mosalamy H, Salman TM, Ashmawey AM, Osama N. Role of chronic E. coli infection in the process of bladder cancer- an experimental study. Infect Agents Cancer. 2012;7(1):19. doi:10.1186/1750-9378-7-19
Mizrahi JD, Surana R, Valle JW, Shroff RT. Pancreatic cancer. The Lancet. 2020;395(10242):2008-2020. doi:10.1016/S0140-6736(20)30974-0
Andersen DK, Korc M, Petersen GM, et al. Diabetes, pancreatogenic diabetes, and pancreatic cancer. Diabetes. 2017;66(5):1103-1110. doi:10.2337/DB16-1477
Pizzato M, Turati F, Rosato V, La Vecchia C. Exploring the link between diabetes and pancreatic cancer. Expert Rev Anticancer Ther. 2019;19(8):681-687. doi:10.1080/14737140.2019.1642109
Popovic K, Smolović B, Martinović M, Vučković L. The relationship between diabetes mellitus and pancreatic cancer-Diabetes mellitus as a Red Flag for pancreatic cancer. Cancer Epidemiol Biomarkers Prev. 2023;32(3):298-305. doi:10.1158/1055-9965.EPI-22-0951/712707/AM/THE-RELATIONSHIP-BETWEEN-DIABETES-MELLITUS-AND
Wang M, Yang Y, Liao Z. Diabetes and cancer: epidemiological and biological links. World J Diabetes. 2020a;11(6):227. doi:10.4239/WJD.V11.I6.227
Saboori S, Rad EY, Birjandi M, Mohiti S, Falahi E. Serum insulin level, HOMA-IR and prostate cancer risk: a systematic review and meta-analysis. Diabetes Metab Syndr. 2019;13(1):110-115. doi:10.1016/J.DSX.2018.08.031
Wang M, Yang Y, Liao Z. Diabetes and cancer: epidemiological and biological links. World J Diabetes. 2020b;11(6):227. doi:10.4239/WJD.V11.I6.227
Xu H, Jiang H, Ding G, et al. Diabetes mellitus and prostate cancer risk of different grade or stage: a systematic review and meta-analysis. Diabetes Res Clin Pract. 2013;99(3):241-249. doi:10.1016/J.DIABRES.2012.12.003
Corona G, Monami M, Rastrelli G, et al. Type 2 diabetes mellitus and testosterone: a meta-analysis study. Int J Androl. 2011;34(6 Pt):528-540. doi:10.1111/J.1365-2605.2010.01117.X
Yoon JM. Pre-existing diabetes mellitus increases the risk of gastric cancer: a meta-analysis. World J Gastroenterol. 2013;19(6):936-945. doi:10.3748/WJG.V19.I6.936
Suh S, Kim K-W. Diabetes and Cancer: Cancer Should Be Screened in Routine Diabetes Assessment 2019a. doi:10.4093/dmj.2019.0177
Ikeda F, Doi Y, Yonemoto K, et al. Hyperglycemia increases risk of gastric cancer posed by helicobacter pylori infection: a population-based cohort study. Gastroenterology. 2009;136(4):1234-1241. doi:10.1053/J.GASTRO.2008.12.045
Castillo JJ, Mull N, Reagan JL, Nemr S, Mitri J. Increased incidence of non-Hodgkin lymphoma, leukemia, and myeloma in patients with diabetes mellitus type 2: a meta-analysis of observational studies. Blood. 2012;119(21):4845-4850. doi:10.1182/BLOOD-2011-06-362830
Mitri J, Castillo J, Pittas AG. Diabetes and risk of Non-Hodgkin's lymphoma. Diabetes Care. 2008;31(12):2391-2397. doi:10.2337/DC08-1034
Pearson-Stuttard J, Bennett J, Cheng YJ, et al. Trends in predominant causes of death in individuals with and without diabetes in England from 2001 to 2018: an epidemiological analysis of linked primary care records. The Lancet Diabetes & Endocrinol. 2021a;9(3):165-173. doi:10.1016/S2213-8587(20)30431-9
Pearson-Stuttard J, Papadimitriou N, Markozannes G, et al. Type 2 diabetes and cancer: an umbrella review of observational and mendelian randomization studies. Cancer Epidemiol Biomarkers Prevent. 2021;30(6):1218-1228. doi:10.1158/1055-9965.EPI-20-1245/671063/AM/TYPE-2-DIABETES-AND-CANCER-AN-UMBRELLA-REVIEW-OF
Barone BB. Long-term all-cause mortality in cancer patients with preexisting diabetes mellitus: a systematic review and meta-analysis. JAMA. 2008;300(23):2754-2764. doi:10.1001/JAMA.2008.824
Tian T, Zhang LQ, Ma XH, Zhou JN, Shen J. Diabetes mellitus and incidence and mortality of gastric cancer: a meta-analysis. Exp Clin Endocrinol Diabetes. 2012;120(4):217-223. doi:10.1055/S-0031-1297969
Lin SY, Hsieh MS, Chen LS, Chiu YH, Yen AMF, Chen THH. Diabetes mellitus associated with the occurrence and prognosis of non-Hodgkin's lymphoma. Eur J Cancer Prev. 2007;16(5):471-478. doi:10.1097/01.CEJ.0000236253.93984.8F
Zhang ZH, Su PY, Hao JH, Sun YH. The role of preexisting diabetes mellitus on incidence and mortality of endometrial cancer: a meta-analysis of prospective cohort studies. Int J Gynecol Cancer. 2013;23(2):294-303. doi:10.1097/IGC.0B013E31827B8430
Seshasai SRK, Kaptoge S, Thompson A, et al. Diabetes mellitus, fasting glucose, and risk of cause-specific death. N Engl J Med. 2011;364(9):829-841. doi:10.1056/NEJMOA1008862
Barone BB, Yeh HC, Snyder CF, et al. Postoperative mortality in cancer patients with preexisting diabetes. Diabetes Care. 2010;33(4):931-939. doi:10.2337/DC09-1721
Dankner R, Roth J. More recent, better designed studies have weakened links between antidiabetes medications and cancer risk. Diabetic Med. 2020;37(2):194-202. doi:10.1111/DME.14179
Onitilo AA, Engel JM, Glurich I, Stankowski RV, Williams GM, Doi SA. Diabetes and cancer II: role of diabetes medications and influence of shared risk factors. Cancer Causes & Control: CCC. 2012b;23(7):991-1008. doi:10.1007/S10552-012-9971-4
Norwood P, Liutkus JF, Haber H, Pintilei E, Boardman MK, Trautmann ME. Safety of exenatide once weekly in patients with type 2 diabetes mellitus treated with a thiazolidinedione alone or in combination with metformin for 2 years. Clin Ther. 2012;34(10):2082-2090. doi:10.1016/J.CLINTHERA.2012.09.007
Stein SA, Lamos EM, Davis SN. A review of the efficacy and safety of oral antidiabetic drugs. Expert Opin Drug Saf. 2013;12(2):153-175. doi:10.1517/14740338.2013.752813
Hemmingsen B, Christensen LL, Wetterslev J, et al. Comparison of metformin and insulin versus insulin alone for type 2 diabetes: systematic review of randomised clinical trials with meta-analyses and trial sequential analyses. BMJ. 2012;344(7853):e1771. doi:10.1136/BMJ.E1771
Kheirandish M, Mahboobi H, Yazdanparast M, Kamal W, Kamal MA. Anti-cancer effects of metformin: recent evidences for its role in prevention and treatment of cancer. Curr Drug Metab. 2018;19(9):793-797. doi:10.2174/1389200219666180416161846
Soranna D, Scotti L, Zambon A, et al. Cancer risk associated with use of metformin and sulfonylurea in type 2 diabetes: a meta-analysis. Oncologist. 2012;17(6):813-822. doi:10.1634/THEONCOLOGIST.2011-0462
Hirsch HA, Iliopoulos D, Tsichlis PN, Struhl K. Metformin selectively targets cancer stem cells, and acts together with chemotherapy to block tumor growth and prolong remission. Cancer Res. 2009;69(19):7507-7511. doi:10.1158/0008-5472.CAN-09-2994
Rattan R, Ali Fehmi R, Munkarah A. Metformin: an emerging new therapeutic option for targeting cancer stem cells and metastasis. J Oncol. 2012;2012:1-12. doi:10.1155/2012/928127
Currie CJ, Poole CD, Gale EAM. The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. Diabetologia. 2009;52(9):1766-1777. doi:10.1007/S00125-009-1440-6
Hsieh MC, Lee TC, Cheng SM, Tu ST, Yen MH, Tseng CH. The influence of type 2 diabetes and glucose-lowering therapies on cancer risk in the Taiwanese. Exp Diabetes Res. 2012;2012:1-6. doi:10.1155/2012/413782
Hwang AL, Haynes K, Hwang WT, Yang YX. Metformin and survival in pancreatic cancer: a retrospective cohort study. Pancreas. 2013;42(7):1054-1059. doi:10.1097/MPA.0B013E3182965A3C
Colmers IN, Bowker SL, Majumdar SR, Johnson JA. Use of thiazolidinediones and the risk of bladder cancer among people with type 2 diabetes: a meta-analysis. Can Med Assoc J. 2012;184(12):E675-E683. doi:10.1503/CMAJ.112102
Tam V, Patel N, Turcotte M, Bossé Y, Paré G, Meyre D. Benefits and limitations of genome-wide association studies. Nat Rev Genet. 2019;20:467-484. doi:10.1038/s41576-019-0127-1
Giovannucci E, Harlan DM, Archer MC, et al. Diabetes and cancer: a consensus report. Diabetes Care. 2010a;33(7):1674. doi:10.2337/DC10-0666